Search results for "infarct"

showing 10 items of 1223 documents

MRI patient selection for endovascular thrombectomy in acute ischemic stroke: correlation between pretreatment diffusion weighted imaging and outcome…

2018

Introduction: Eligibility for endovascular treatment (EVT) in patients with acute ischemic stroke (AIS) depends, amongst other factors, on CT- or MR-based scores. The aim of this study was to investigate the role of Alberta Stroke Program Early CT score based on diffusion weighted imaging (MR-ASPECT) in the assessment of brain damage pre-EVT, patient selection for EVT and outcome. Materials and methods: We included in this study patients with National Institute of Health stroke score (NIHSS) at admission ≥ 8, MR-ASPECT ≥ 5 and anterior AIS, who were treated with EVT in our hospital. All patients were clinically evaluated at admission, post-EVT, discharge and at 3-month follow-up. We used MR…

Malemedicine.medical_specialtyRadiology Nuclear Medicine and Imagingmedicine.medical_treatmentDiffusion weighted imaging; Magnetic resonance; Revascularization; Stroke; Aged; Brain Ischemia; Diffusion Magnetic Resonance Imaging; Endovascular Procedures; Female; Humans; Male; Stroke; Thrombectomy; Tomography X-Ray Computed; Treatment Outcome; Patient Selection; Radiology Nuclear Medicine and ImagingRevascularizationBrain Ischemia03 medical and health sciences0302 clinical medicinemedicineHumans030212 general & internal medicineStrokeNeuroradiologyAgedThrombectomymedicine.diagnostic_testbusiness.industryCerebral infarctionPatient SelectionRevascularizationEndovascular ProceduresInterventional radiologyMagnetic resonance imagingDiffusion weighted imagingGeneral MedicineThrombolysismedicine.diseaseCollateral circulationStrokeDiffusion Magnetic Resonance ImagingTreatment OutcomeMagnetic resonanceFemaleRadiologybusinessTomography X-Ray Computed030217 neurology & neurosurgery
researchProduct

A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions

2018

Aims: The clinical value of percutaneous coronary intervention (PCI) for chronic coronary total occlusions (CTOs) is not established by randomized trials. This study should compare the benefit of PCI vs. optimal medical therapy (OMT) on the health status in patients with at least one CTO.Method and results: Three hundred and ninety-six patients were enrolled in a prospective randomized, multicentre, open-label, and controlled clinical trial to compare the treatment by PCI with OMT with a 2:1 randomization ratio. The primary endpoint was the change in health status assessed by the Seattle angina questionnaire (SAQ) between baseline and 12 months follow-up. Fifty-two percent of patients have …

Malemedicine.medical_specialtyRandomizationmedicine.medical_treatmentAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologyAngina Pectorislaw.inventionAngina03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionRandomized controlled triallawInternal medicinemedicineClinical endpointHumansPercutaneous transluminal interventioncardiovascular diseases030212 general & internal medicineMyocardial infarctionOptimal medical therapyAgedNitratesbusiness.industryAngina PectoriPercutaneous coronary interventionAngiotensin-Converting Enzyme InhibitorMiddle Agedmedicine.diseaseClinical trialCoronary OcclusionChronic coronary occlusion; EQ-5D; Optimal medical therapy; Percutaneous transluminal intervention; Seattle angina questionnaire; Cardiology and Cardiovascular MedicineConventional PCIChronic DiseaseChronic coronary occlusionQuality of LifeSeattle angina questionnaireFemaleHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitors
researchProduct

The predictive value of heart-type fatty acid-binding protein is independent from symptom duration in normotensive patients with pulmonary embolism.

2013

Heart-type fatty acid-binding protein (H-FABP) is a useful biomarker for risk stratification of patients with pulmonary embolism (PE). In patients with acute myocardial infarction, H-FABP plasma concentrations rise after 30 minutes and return to normal within 20-24 hours. We tested whether the predictive value of H-FABP is affected by the duration of symptoms prior to diagnosis in patients with PE.We prospectively studied 257 consecutive normotensive patients with confirmed symptomatic PE.Patients with acute (24 hours; n=150) symptom onset presented more often with syncope (28.7% vs. 6.5%; p0.001) compared to patients with symptoms ≥ 24 hours (n=107); other baseline characteristics, comorbi…

Malemedicine.medical_specialtyRenal function030204 cardiovascular system & hematologyFatty Acid-Binding Proteins03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumans030212 general & internal medicineMyocardial infarctionProspective StudiesAgedbusiness.industryArea under the curveHematologyOdds ratioMiddle Agedmedicine.diseasePrognosisConfidence interval3. Good healthPulmonary embolismHeart-type fatty acid binding proteinCardiologyBiomarker (medicine)lipids (amino acids peptides and proteins)FemalebusinessPulmonary EmbolismFatty Acid Binding Protein 3Thrombosis research
researchProduct

Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSC…

2018

Abstract Aims Resting heart rate (RHR) has been shown to be associated with cardiovascular outcomes in various conditions. It is unknown whether different levels of RHR and different associations with cardiovascular outcomes occur in patients with or without diabetes, because the impact of autonomic neuropathy on vascular vulnerability might be stronger in diabetes. Methods and results We examined 30 937 patients aged 55 years or older with a history of or at high risk for cardiovascular disease and after myocardial infarction, stroke, or with proven peripheral vascular disease from the ONTARGET and TRANSCEND trials investigating ramipril, telmisartan, and their combination followed for a m…

Malemedicine.medical_specialtyRestHeart failure030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineHeart RateRisk FactorsInternal medicineDiabetes mellitusmedicineDiabetes MellitusHumansMyocardial infarctionProspective StudiesONTARGETStrokeProportional hazards modelbusiness.industryHazard ratioDiabetesAtrial fibrillation030229 sport sciencesMiddle Agedmedicine.diseaseCardiovascular riskMyocardial infarctionBlood pressureCardiovascular DiseasesHeart Disease Risk FactorsHeart failureCardiologyBlood pressureFemaleCardiology and Cardiovascular MedicinebusinessTRANSCENDEuropean heart journal
researchProduct

La concentración sanguínea de PGC-1a predice miocardio salvado y remodelado ventricular tras infarto agudo de miocardio con elevación del segmento ST

2015

et al.

Malemedicine.medical_specialtyST-segment elevation acute myocardial infarctionMyocardial InfarctionIschemiaPGC-1αMagnetic Resonance Imaging CineInfarctionRemodelado ventricularElectrocardiographyCardiac magnetic resonance imagingVentricular remodelingInternal medicineEdemamedicineHumansST segmentProspective Studiescardiovascular diseasesMyocardial infarctionVentricular remodelingHeat-Shock ProteinsVentricular Remodelingmedicine.diagnostic_testbusiness.industryMyocardiumEstrés oxidativoStroke VolumeMagnetic resonance imagingGeneral MedicineMiddle AgedPrognosismedicine.diseasePeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaInfarto agudo de miocardio con elevación del segmento STMetabolismo oxidativoOxidative stresscardiovascular systemCardiologyOxidative metabolismFemalemedicine.symptombusinessFollow-Up StudiesTranscription FactorsRevista Española de Cardiología (English Edition)
researchProduct

COPD significantly increases cerebral and cardiovascular events in hypertensives

2021

AbstractEssential hypertension and chronic obstructive pulmonary disease often coexist in the same patient. The aim of this study was to evaluate whether the addition of chronic obstructive pulmonary disease modifies the risk of cardiovascular events in hypertensives. We enrolled 1728 hypertensives. Study outcomes included fatal and non-fatal cardiovascular stroke and myocardial infarction, and cardiovascular death. During a mean follow-up of 57 months there were 205 major adverse cardiovascular events (2.47 per 100 pts/yr): cardiac (n117; 1.41 per 100 pts/yr) and cerebrovascular (n = 77; 0.93 per 100 pts/yr). In hypertensives with chronic obstructive pulmonary disease we observed a greater…

Malemedicine.medical_specialtyScienceCardiologyPulmonary disease030204 cardiovascular system & hematologyEssential hypertensionArticleCardiovascular deathPulmonary Disease Chronic Obstructive03 medical and health sciencesMedical research0302 clinical medicineInternal medicinemedicineHumansMyocardial infarctionStrokeAgedessential hypertension; chronic obstructive; pulmonary diseaseCOPDMultidisciplinarybusiness.industryIncidenceIncidence (epidemiology)QRespiratory diseaseRMiddle Agedmedicine.diseaseRisk factors030228 respiratory systemHypertensionCardiologyMedicineFemaleCOPD Hypertensionbusiness
researchProduct

The importance of including uric acid in the definition of metabolic syndrome when assessing the mortality risk

2021

Abstract Introduction Serum uric acid (SUA) has been depicted as a contributory causal factor in metabolic syndrome (MS), which in turn, portends unfavourable prognosis. Aim We assessed the prognostic role of SUA in patients with and without MS. Methods We used data from the multicentre Uric Acid Right for Heart Health study and considered cardiovascular mortality (CVM) as death due to fatal myocardial infarction, stroke, sudden cardiac death, or heart failure. Results A total of 9589 subjects (median age 58.5 years, 45% males) were included in the analysis, and 5100 (53%) patients had a final diagnosis of MS. After a median follow-up of 142 months, we observed 558 events. Using a previousl…

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaCardiovascular mortalityPrognosiSudden cardiac deathchemistry.chemical_compoundSerum uric acidRisk FactorsInternal medicineCause of DeathmedicineHumansSerum uric acid.Myocardial infarctionCardiovascular mortality; Metabolic syndrome; Prognosis; Serum uric acidStrokeRetrospective StudiesOriginal Paperbusiness.industryProportional hazards modelHazard ratioGeneral MedicineMiddle Agedmedicine.diseasePrognosisMetabolic syndromeUric AcidSurvival RatechemistryItalyCardiovascular DiseasesHeart failureCardiologyUric acidFemaleMetabolic syndromeCardiology and Cardiovascular MedicinebusinessBiomarkersFollow-Up Studies
researchProduct

Immune-inflammatory markers and arterial stiffness indexes in subjects with acute ischemic stroke.

2010

Abstract No study has yet evaluated the relationship between arterial stiffness indexes and immuno-inflammatory pathway in patients with an acute cardiovascular or cerebrovascular event. The aim of our study was to evaluate in patients with acute ischemic stroke the relationship between immune-inflammatory markers and arterial stiffness indexes. Methods 107 subjects with acute ischemic stroke and 107 controls without stroke. We evaluated plasma levels of C-reactive protein (CRP), interleukin-1beta (IL-1β), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and interleukin-10 (IL-10), E-selectin, P-selectin, intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1…

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaEmbolismTissue plasminogen activatorVon Willebrand factorIschemiaInternal medicinevon Willebrand FactormedicineHumanscardiovascular diseasesStrokePulse wave velocityAgedAged 80 and overInflammationbiologybusiness.industryCerebral infarctionMiddle Agedmedicine.diseaseAtherosclerosisischemic stroke arterial stiffnessSurgeryStrokeCarotid ArteriesImmune SystemAcute Diseasecardiovascular systemArterial stiffnessCardiologybiology.proteinCytokinesAortic stiffnessFemaleCardiology and Cardiovascular MedicinebusinessPlasminogen activatorcirculatory and respiratory physiologymedicine.drugAtherosclerosis
researchProduct

Identification of the Uric Acid Thresholds Predicting an Increased Total and Cardiovascular Mortality Over 20 Years

2020

Serum uric acid (SUA) levels discriminating across the different strata of cardiovascular risk is still unknown. By utilizing a large population-based database, we assessed the threshold of SUA that increases the risk of total mortality and cardiovascular mortality (CVM). The URRAH study (Uric Acid Right for Heart Health) is a multicentre retrospective, observational study, which collected data from several large population-based longitudinal studies in Italy and subjects recruited in the hypertension clinics of the Italian Society of Hypertension. Total mortality was defined as mortality for any cause, CVM as death due to fatal myocardial infarction, stroke, sudden cardiac death, or heart…

Malemedicine.medical_specialtySettore MED/09 - Medicina Internaepidemiology; heart failure; humans; risk; uric acid; Cause of Death; Female; Humans; Italy; Male; Middle Aged; Mortality; Practice Patterns Physicians'; Quality Improvement; Risk Assessment; Risk Factors; Uric Acid; Cardiovascular Diseases; Hypertension; Hyperuricemiaheart failurePractice PatternsHyperuricemia030204 cardiovascular system & hematologyepidemiology; heart failure; humans; risk; uric acidRisk AssessmentSudden cardiac death03 medical and health sciences0302 clinical medicineuric acidRisk FactorsInternal medicineCause of DeathEpidemiologyInternal MedicineMedicine030212 general & internal medicineHyperuricemiaMyocardial infarctionhumanMortalityPractice Patterns Physicians'humansStrokeriskEpidemiology heart failure humans risk uric acid.Physicians'business.industryProportional hazards modelHazard ratioUric acid cardiovascular mortality epidemiologyMiddle Agedmedicine.diseaseQuality ImprovementItalyCardiovascular DiseasesHeart failureHypertensionFemaleepidemiologybusiness
researchProduct

Benefit of Targeting a LDL (Low-Density Lipoprotein) Cholesterol \textless70 mg/dL During 5 Years After Ischemic Stroke

2020

Background and Purpose— The TST trial (Treat Stroke to Target) evaluated the benefit of targeting a LDL (low-density lipoprotein) cholesterol of <70 mg/dL to reduce the risk of cardiovascular events in 2860 patients with ischemic stroke with atherosclerotic stenosis of cerebral vasculature or aortic arch plaque >4 mm, in a French and Korean population. The follow-up lasted a median of 5.3 years in French patients (similar to the median follow-up time in the SPARCL trial [Stroke Prevention by Aggressive Reduction in Cholesterol Level]) and 2.0 years in Korean patients. Exposure duration to statin is a well-known driver for cardiovascular risk reduction. We report here the TST results …

Malemedicine.medical_specialtyStatinTime Factorsmedicine.drug_class[SDV]Life Sciences [q-bio]Brain IschemiaLDLchemistry.chemical_compoundDrug Delivery SystemsEzetimibeInternal medicinemedicineClinical endpointHumansangiographyMyocardial infarctionStrokeAgedAdvanced and Specialized NursingCerebral infarctionCholesterolbusiness.industryAnticholesteremic Agentsinformed consentcholesterolCholesterol LDLMiddle Agedmedicine.diseaseEzetimibestroke[SDV] Life Sciences [q-bio]aortachemistryNumber needed to treatCardiologyFemaleNeurology (clinical)Cardiology and Cardiovascular Medicinebusinessmedicine.drug
researchProduct